Compare Amgen, Inc. (AMGN) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Amgen, Inc. trades at $356.83 (market cap $196.12B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.63. The key difference: Amgen, Inc. pays a 2.77% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | VCIT | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Fixed Income |
52-Week High | $388.16 | $84.82 |
52-Week Low | $271.18 | $81.54 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.81, down 0.13% with a bearish technical signal. The fund maintains a low 0.03% expense ratio and offers monthly dividend distributions, with recent payouts around $0.33-$0.34. Technical indicators show oversold conditions with RSI at 19.28, while moving averages signal bearish momentum. The fund provides exposure to over 2,000 investment-grade corporate bonds with a current SEC yield around 5.17%.
VCIT offers income-focused investors a balanced approach to intermediate-term corporate bonds with competitive yields and low costs. Key risks include interest rate sensitivity and corporate credit quality concerns. The fund's diversification across investment-grade issuers provides stability, though economic uncertainty could impact bond valuations. Current technical weakness may present entry opportunities for yield-seeking investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
